Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

NCT01915108 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Respiratory Complication

Interventions

DRUG: Remifentanil

Sponsor

Sangjin Park